SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Healthcare IT

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2115778

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2115778

Digital Therapeutics/DTx Market by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031

PUBLISHED:
PAGES: 415 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global digital therapeutics market is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031. The growth of the digital therapeutics market is being driven by the increasing prevalence of chronic diseases, rising demand for personalized and remote patient care, and the growing focus on improving clinical outcomes while reducing healthcare costs. Healthcare providers, payers, and employers are increasingly adopting evidence-based digital therapeutics to prevent, manage, and treat conditions such as diabetes, obesity, cardiovascular diseases, musculoskeletal disorders, insomnia, and mental health disorders through clinically validated software interventions.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsOffering, Product Type, Application, Revenue Model, Sales Channel, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East and Africa

Furthermore, regulatory and reimbursement support for digital health solutions continues to strengthen. In March 2025, the European Health Data Space (EHDS) Regulation entered into force, establishing a harmonized framework for the secure exchange and secondary use of electronic health data across the European Union, which is expected to facilitate the integration and scalability of digital therapeutics. In addition, continued advances in artificial intelligence (AI), remote patient monitoring, wearable technologies, and interoperable digital health infrastructure are enhancing the personalization, accessibility, and effectiveness of digital therapeutics while supporting value-based healthcare delivery. However, market growth may be constrained by fragmented reimbursement policies across countries, evolving regulatory requirements, concerns regarding data privacy and cybersecurity, limited awareness among healthcare professionals, and the need for robust clinical and real-world evidence to demonstrate long-term therapeutic and economic value.

Digital Therapeutics/DTx Market - IMG1

"In 2025, the hospitals segment accounted for the largest share of the digital therapeutics market, by end user."

By end user, hospitals accounted for the largest share of the digital therapeutics market in 2025. Their leading position is driven by the increasing integration of digital therapeutics into multidisciplinary care pathways for chronic disease management, mental health, rehabilitation, and post-acute care. Hospitals are adopting these solutions to complement conventional therapies, improve patient engagement, support continuous remote monitoring, and enhance treatment adherence beyond inpatient settings. The growing emphasis on value-based care, reducing hospital readmissions, and delivering personalized, data-driven interventions has further accelerated the deployment of digital therapeutics across hospital networks. In addition, the availability of integrated digital health infrastructure, established clinical workflows, and stronger collaboration with technology developers and healthcare providers has enabled hospitals to effectively implement evidence-based digital therapeutic solutions at scale. As healthcare systems continue to prioritize connected care models and long-term disease management, hospitals have maintained their position as the largest end-user segment in the digital therapeutics market.

"The B2C segment, by sales channel, is expected to register the fastest growth during the forecast period."

By sales channel, the B2C (business-to-consumer) segment is expected to be the fastest-growing segment in the digital therapeutics market during the forecast period. This growth is driven by increasing consumer awareness of digital health solutions, rising demand for convenient self-management tools, and growing acceptance of preventive and wellness-focused care. Consumers are increasingly adopting digital therapeutics through mobile applications and connected devices to manage conditions such as obesity, sleep disorders, stress, anxiety, diabetes, and other lifestyle-related diseases without relying solely on traditional healthcare settings. The rapid expansion of smartphone penetration, wearable health technologies, and subscription-based digital health platforms has made these solutions more accessible and affordable for a broader population. Additionally, advancements in artificial intelligence, personalized behavioral coaching, and real-time health insights are improving user engagement and long-term adherence, while direct-to-consumer marketing strategies and expanding digital distribution channels are further accelerating the adoption of B2C digital therapeutics throughout the forecast period.

"Asia Pacific to witness the highest growth rate during the forecast period."

The Asia Pacific region is projected to register the highest growth rate in the digital therapeutics market during the forecast period. This growth is driven by the rising prevalence of chronic diseases, rapid healthcare digitalization, increasing smartphone adoption, and supportive government initiatives promoting digital health infrastructure across the region. Countries such as China, Japan, India, South Korea, Singapore, and Australia are expanding investments in telehealth, remote patient monitoring, artificial intelligence (AI)-enabled healthcare, and digital disease management to improve healthcare accessibility and address the growing burden of diabetes, cardiovascular diseases, obesity, and mental health disorders. Furthermore, the increasing presence of digital health startups, expanding collaborations between healthcare providers and technology companies, and growing reimbursement support for digital health solutions are accelerating the adoption of digital therapeutics across the region. Recent industry developments further reinforce this momentum; in February 2024, TruDoc Healthcare acquired Wellthy Therapeutics, one of Asia's leading digital therapeutics companies, to strengthen its digital healthcare capabilities across the GCC region while expanding into India, combining Wellthy's clinically validated digital therapeutics platform with TruDoc's virtual primary care and remote healthcare services. This acquisition highlights the increasing strategic investments in digital therapeutics and reinforces Asia Pacific's position as a key hub for innovation and commercialization in digital health.

The breakdown of primary participants is as mentioned below:

  • By Company Type - Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
  • By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
  • By Region - North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, and Latin America: 2%

Key Players in the Digital Therapeutics Market

The key players functioning in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), and Sword Health, Inc. (Portugal).

Research Coverage:

This research report categorizes the digital therapeutics market by offering (software/platforms, therapeutic programs, immersive & interface-based therapeutics), product type (prescription digital therapeutics, non-prescription digital therapeutics), application (treatment & care-related applications, preventive applications), revenue model (subscription-based model, licensing (enterprise/SAAS) model, outcome-/value-based model), sales channel (B2B sales channel, B2C sales channel), end user (healthcare provider, payers, employers, patients/individuals, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies (contracts, partnerships, agreements, product & service launches, mergers, and acquisitions), and recent developments associated with the digital therapeutics market. Competitive analysis of upcoming startups in the digital therapeutics market ecosystem is covered in this report.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of key drivers (rising prevalence of chronic and behavioral health conditions, shift toward value-based and patient-centered care, expansion of smartphone adoption and digital health infrastructure, growing clinical evidence and regulatory recognition), restraints (limited reimbursement and inconsistent payment pathways, regulatory complexity and evolving approval frameworks), opportunities (expansion into new therapeutic areas, integration with AI and personalized medicine, increasing partnerships with pharmaceutical and healthcare organizations), and challenges (sustaining long-term patient engagement and adherence, demonstrating long-term clinical and economic value) influencing the growth of the digital therapeutics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the digital therapeutics market.
  • Market Development: Comprehensive information on the lucrative emerging markets, offering, product type, application, revenue model, sales channel, end user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the digital therapeutics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the digital therapeutics market like Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), Sword Health, Inc. (Portugal).
Show more
Product Code: HIT 4407

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
  • 3.2 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE & COUNTRY
  • 3.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Rising prevalence of chronic and behavioral health conditions
      • 4.2.1.2 Shift toward value-based and patient-centered care
      • 4.2.1.3 Expansion of smartphone adoption and digital health infrastructure
      • 4.2.1.4 Growing clinical evidence and regulatory recognition
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Limited reimbursement and inconsistent payment pathways
      • 4.2.2.2 Regulatory complexity and evolving approval frameworks
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Expansion into new therapeutic areas
      • 4.2.3.2 Integration with AI and personalized medicine
      • 4.2.3.3 Increasing partnerships with pharmaceutical and healthcare organizations
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Sustaining long-term patient engagement and adherence
      • 4.2.4.2 Demonstrating long-term clinical and economic value
  • 4.3 UNMET NEEDS & WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF SUBSTITUTES
    • 5.1.4 THREAT OF NEW ENTRANTS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
    • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.3.2 DATA INPUTS & TECHNOLOGY INFRASTRUCTURE
    • 5.3.3 PLATFORM DEVELOPMENT & DEPLOYMENT
    • 5.3.4 DISTRIBUTION
    • 5.3.5 MARKETING & SALES
    • 5.3.6 POST-SALES SERVICES
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY OFFERING (2025)
    • 5.5.2 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY REGION (2025)
  • 5.6 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 CASE STUDY ANALYSIS
  • 5.10 IMPACT OF 2025 US TARIFFS ON DIGITAL THERAPEUTICS MARKET
    • 5.10.1 INTRODUCTION
    • 5.10.2 KEY TARIFF RATES
    • 5.10.3 PRICE IMPACT ANALYSIS
    • 5.10.4 IMPACT ON COUNTRY/REGION
      • 5.10.4.1 US
      • 5.10.4.2 Europe
      • 5.10.4.3 Asia Pacific
    • 5.10.5 IMPACT ON END-USE INDUSTRY
      • 5.10.5.1 Healthcare providers
      • 5.10.5.2 Payers
      • 5.10.5.3 Employers
      • 5.10.5.4 Patients/Individuals
      • 5.10.5.5 Other end users

6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 SOFTWARE AS A MEDICAL DEVICE (SAMD)
    • 6.1.2 MOBILE HEALTH (MHEALTH) APPLICATIONS
    • 6.1.3 ARTIFICIAL INTELLIGENCE (AI) & MACHINE LEARNING (ML)
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 REMOTE PATIENT MONITORING (RPM)
    • 6.2.2 INTERNET OF MEDICAL THINGS (IOMT)
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 ELECTRONIC HEALTH RECORDS (EHR/EMR)
    • 6.3.2 DIGITAL DIAGNOSTICS
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 PATENT PUBLICATION TRENDS FOR DIGITAL THERAPEUTICS MARKET
    • 6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
  • 6.6 FUTURE APPLICATIONS
    • 6.6.1 AI-ENABLED PERSONALIZED THERAPEUTICS & CLINICAL DECISION SUPPORT
    • 6.6.2 CONTINUOUS REMOTE CARE & DIGITAL HEALTH ECOSYSTEMS
    • 6.6.3 DIGITAL BIOMARKER-DRIVEN PREVENTIVE & PRECISION CARE
  • 6.7 IMPACT OF AI/GEN AI ON DIGITAL THERAPEUTICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL THERAPEUTICS MARKET
    • 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
      • 6.7.3.1 AI technologies in digital therapeutics
    • 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
      • 6.7.4.1 Digital health & telehealth market
      • 6.7.4.2 Remote patient monitoring (RPM) market
      • 6.7.4.3 Electronic health records (EHR/EMR) market
    • 6.7.5 USER READINESS & IMPACT ASSESSMENT
      • 6.7.5.1 User readiness
        • 6.7.5.1.1 User A: Healthcare providers
        • 6.7.5.1.2 User B: Payers
      • 6.7.5.2 Impact assessment
        • 6.7.5.2.1 User A: Healthcare providers
          • 6.7.5.2.1.1 Implementation
          • 6.7.5.2.1.2 Impact
        • 6.7.5.2.2 User B: Payers
          • 6.7.5.2.2.1 Implementation
          • 6.7.5.2.2.2 Impact

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 REGULATORY FRAMEWORK
      • 7.1.2.1 North America
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
      • 7.1.2.4 Latin America
      • 7.1.2.5 Middle East & Africa
    • 7.1.3 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 INTRODUCTION
  • 8.2 DECISION-MAKING PROCESS
  • 8.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.3.2 BUYING CRITERIA
  • 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
    • 8.5.1 UNMET NEEDS
    • 8.5.2 END-USER EXPECTATIONS
  • 8.6 MARKET PROFITABILITY

9 DIGITAL THERAPEUTICS MARKET, BY OFFERING

  • 9.1 INTRODUCTION
  • 9.2 SOFTWARE/PLATFORMS
    • 9.2.1 AI-DRIVEN PLATFORM ARCHITECTURES AND EXPANDING REGULATORY PATHWAYS TO DRIVE MARKET EXPANSION
  • 9.3 THERAPEUTIC PROGRAMS
    • 9.3.1 EXPANDING FDA CLEARANCES ACROSS NEW INDICATIONS AND MATURING REIMBURSEMENT CODES TO DRIVE PROGRAM ADOPTION
  • 9.4 IMMERSIVE & INTERFACE-BASED THERAPEUTICS
    • 9.4.1 GROWING CLINICAL EVIDENCE AND NEW REIMBURSEMENT CODES FOR VR-DELIVERED CARE TO DRIVE SEGMENT GROWTH

10 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE

  • 10.1 INTRODUCTION
  • 10.2 PRESCRIPTION DIGITAL THERAPEUTICS
    • 10.2.1 REGULATORY APPROVALS AND GROWING CLINICAL VALIDATION TO ACCELERATE ADOPTION OF PRESCRIPTION DIGITAL THERAPEUTICS
  • 10.3 NON-PRESCRIPTION DIGITAL THERAPEUTICS
    • 10.3.1 INCREASING CONSUMER ACCESSIBILITY AND DIGITAL HEALTH ADOPTION TO ACCELERATE GROWTH OF NON-PRESCRIPTION DIGITAL THERAPEUTICS

11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 TREATMENT & CARE-RELATED APPLICATIONS
    • 11.2.1 DIABETES
      • 11.2.1.1 Rising global diabetes burden and connected digital care to accelerate adoption of digital therapeutics
    • 11.2.2 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS
      • 11.2.2.1 Rising mental health burden and AI-enabled behavioral care to accelerate adoption of digital therapeutics for CNS disorders
    • 11.2.3 SMOKING CESSATION
      • 11.2.3.1 Increasing tobacco control initiatives and behavioral interventions to boost adoption
    • 11.2.4 CHRONIC RESPIRATORY DISEASES
      • 11.2.4.1 Rising burden of chronic respiratory conditions and remote disease management to fuel growth
    • 11.2.5 MUSCULOSKELETAL DISORDERS
      • 11.2.5.1 Rising burden of musculoskeletal conditions and AI-enabled rehabilitation to support market growth
    • 11.2.6 CARDIOVASCULAR DISORDERS
      • 11.2.6.1 Growing cardiovascular disease burden and remote cardiac care to contribute to market growth
    • 11.2.7 MEDICATION ADHERENCE
      • 11.2.7.1 Growing need to improve treatment compliance and long-term outcomes to drive growth
    • 11.2.8 SLEEP DISORDERS
      • 11.2.8.1 Rising prevalence of sleep disorders and connected sleep care to accelerate adoption of digital therapeutics
    • 11.2.9 REHABILITATION & PATIENT CARE
      • 11.2.9.1 Digital rehabilitation platforms to transform recovery beyond traditional clinical settings
    • 11.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
      • 11.2.10.1 Digital therapeutics to expand access to evidence-based addiction treatment and long-term recovery support
    • 11.2.11 OTHER TREATMENT & CARE-RELATED APPLICATIONS
  • 11.3 PREVENTIVE APPLICATIONS
    • 11.3.1 PREDIABETES
      • 11.3.1.1 Early risk identification and lifestyle intervention to drive adoption of digital therapeutics for prediabetes
    • 11.3.2 OBESITY & WEIGHT MANAGEMENT
      • 11.3.2.1 Digital therapeutics to complement GLP-1 therapies and enable sustainable weight management
    • 11.3.3 NUTRITION & LIFESTYLE MANAGEMENT
      • 11.3.3.1 Personalized nutrition and lifestyle coaching to expand role of digital therapeutics in preventive healthcare
    • 11.3.4 OTHER PREVENTIVE APPLICATIONS

12 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL

  • 12.1 INTRODUCTION
  • 12.2 SUBSCRIPTION-BASED MODELS
    • 12.2.1 CONTINUOUS CARE DELIVERY AND RECURRING PATIENT ENGAGEMENT TO STRENGTHEN ADOPTION
  • 12.3 LICENSING (ENTERPRISE/SAAS) MODELS
    • 12.3.1 ENTERPRISE ADOPTION AND SCALABLE CLOUD DEPLOYMENTS TO DRIVE GROWTH OF LICENSING (ENTERPRISE/SAAS) MODELS
  • 12.4 OUTCOME-/VALUE-BASED MODELS
    • 12.4.1 GROWING SHIFT TOWARD PERFORMANCE-BASED REIMBURSEMENT TO DRIVE ADOPTION OF OUTCOME-/VALUE-BASED MODELS

13 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL

  • 13.1 INTRODUCTION
  • 13.2 B2B SALES CHANNELS
    • 13.2.1 HEALTHCARE ECOSYSTEM PARTNERSHIPS AND REIMBURSEMENT EXPANSION TO DRIVE B2B LEADERSHIP IN DIGITAL THERAPEUTICS
  • 13.3 B2C SALES CHANNELS
    • 13.3.1 CONSUMER-CENTRIC DIGITAL HEALTH ADOPTION AND PREVENTIVE CARE TRENDS TO ACCELERATE B2C GROWTH

14 DIGITAL THERAPEUTICS MARKET, BY END USER

  • 14.1 INTRODUCTION
  • 14.2 HEALTHCARE PROVIDERS
    • 14.2.1 HOSPITALS
      • 14.2.1.1 Expanding digital care delivery to drive hospital adoption of digital therapeutics
    • 14.2.2 SPECIALTY CLINICS
      • 14.2.2.1 Condition-specific care delivery to accelerate digital therapeutics adoption in specialty clinics
    • 14.2.3 DIAGNOSTIC & REHABILITATION CENTERS
      • 14.2.3.1 Digital rehabilitation and outcome-focused care to drive adoption in diagnostic & rehabilitation centers
    • 14.2.4 OTHER HEALTHCARE PROVIDERS
  • 14.3 HEALTHCARE PAYERS
    • 14.3.1 PUBLIC PAYERS
      • 14.3.1.1 Government-led digital health programs to expand role of digital therapeutics in public healthcare
    • 14.3.2 PRIVATE PAYERS
      • 14.3.2.1 Outcome-based insurance models and employer health strategies to boost digital therapeutics adoption among private payers
  • 14.4 EMPLOYERS
    • 14.4.1 GROWING EMPHASIS ON PREVENTIVE HEALTHCARE AND VALUE-BASED EMPLOYEE BENEFITS TO ACCELERATE ADOPTION ACROSS EMPLOYER SEGMENT
  • 14.5 PATIENTS/INDIVIDUALS
    • 14.5.1 INCREASING PREFERENCE FOR SELF-MANAGED AND PREVENTIVE HEALTHCARE TO DRIVE ADOPTION IN SEGMENT
  • 14.6 OTHER END USERS

15 DIGITAL THERAPEUTICS MARKET, BY REGION

  • 15.1 INTRODUCTION
  • 15.2 NORTH AMERICA
    • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 15.2.2 US
      • 15.2.2.1 Expanding reimbursement, AI-powered care, and chronic disease management to drive digital therapeutics adoption
    • 15.2.3 CANADA
      • 15.2.3.1 Digital health expansion and public healthcare innovation to support digital therapeutics adoption
  • 15.3 EUROPE
    • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 15.3.2 GERMANY
      • 15.3.2.1 Strong digital health ecosystem and favorable reimbursement to drive digital therapeutics adoption
    • 15.3.3 FRANCE
      • 15.3.3.1 Digital therapeutics access and reimbursement pathway development to boost market expansion
    • 15.3.4 UK
      • 15.3.4.1 NHS digital transformation and strong regulatory support to accelerate adoption
    • 15.3.5 ITALY
      • 15.3.5.1 Healthcare digitalization and chronic disease burden to create growth opportunities for digital therapeutics
    • 15.3.6 SPAIN
      • 15.3.6.1 Healthcare digitalization and telehealth expansion to drive digital therapeutics adoption
    • 15.3.7 REST OF EUROPE
  • 15.4 ASIA PACIFIC
    • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 15.4.2 CHINA
      • 15.4.2.1 Software-driven therapeutics to gain regulatory momentum amid government digital health push
    • 15.4.3 JAPAN
      • 15.4.3.1 Demographic pressures and regulatory reform to drive cautious digital therapeutics adoption
    • 15.4.4 INDIA
      • 15.4.4.1 Regulatory formalization and selective capital deployment to shape early-stage growth
    • 15.4.5 AUSTRALIA
      • 15.4.5.1 Strong digital health ecosystem and telehealth adoption to drive digital therapeutics growth
    • 15.4.6 SOUTH KOREA
      • 15.4.6.1 Government digital health initiatives and AI innovation to accelerate digital therapeutics adoption
    • 15.4.7 REST OF ASIA PACIFIC
  • 15.5 LATIN AMERICA
    • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 15.5.2 BRAZIL
      • 15.5.2.1 Universal healthcare expansion and digital health innovation to drive digital therapeutics demand
    • 15.5.3 MEXICO
      • 15.5.3.1 Growing public health needs and expanding digital access to support market growth
    • 15.5.4 REST OF LATIN AMERICA
  • 15.6 MIDDLE EAST & AFRICA
    • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 15.6.2 GCC COUNTRIES
      • 15.6.2.1 National digital health guidance to accelerate software-based therapeutic adoption
      • 15.6.2.2 Saudi Arabia
        • 15.6.2.2.1 Vision 2030 digital health guidance to establish formal pathway for software-based therapeutics
      • 15.6.2.3 UAE
        • 15.6.2.3.1 Digital transformation and healthcare innovation to support digital therapeutics growth
      • 15.6.2.4 Rest of Gcc Countries
    • 15.6.3 SOUTH AFRICA
      • 15.6.3.1 Digital health expansion and high disease burden to create opportunities for digital therapeutics
    • 15.6.4 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

  • 16.1 OVERVIEW
  • 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET
  • 16.3 REVENUE ANALYSIS, 2021-2025
  • 16.4 MARKET SHARE ANALYSIS, 2025
  • 16.5 BRAND/PRODUCT COMPARISON
  • 16.6 COMPANY VALUATION & FINANCIAL METRICS
    • 16.6.1 FINANCIAL METRICS
    • 16.6.2 COMPANY VALUATION
  • 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 16.7.1 STARS
    • 16.7.2 EMERGING LEADERS
    • 16.7.3 PERVASIVE PLAYERS
    • 16.7.4 PARTICIPANTS
    • 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 16.7.5.1 Company footprint
      • 16.7.5.2 Region footprint
      • 16.7.5.3 Offering footprint
      • 16.7.5.4 Application footprint
      • 16.7.5.5 Revenue model footprint
      • 16.7.5.6 End-user footprint
  • 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 16.8.1 PROGRESSIVE COMPANIES
    • 16.8.2 RESPONSIVE COMPANIES
    • 16.8.3 DYNAMIC COMPANIES
    • 16.8.4 STARTING BLOCKS
    • 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 16.8.5.1 Detailed list of key startups/SMEs
      • 16.8.5.2 Competitive benchmarking of startups/SMEs
  • 16.9 COMPETITIVE SCENARIO
    • 16.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
    • 16.9.2 DEALS
    • 16.9.3 OTHER DEVELOPMENTS

17 COMPANY PROFILES

  • 17.1 KEY PLAYERS
    • 17.1.1 TELADOC HEALTH, INC.
      • 17.1.1.1 Business overview
      • 17.1.1.2 Products & services offered
      • 17.1.1.3 Recent developments
        • 17.1.1.3.1 Product launches & enhancements
        • 17.1.1.3.2 Deals
      • 17.1.1.4 MnM view
        • 17.1.1.4.1 Right to win
        • 17.1.1.4.2 Strategic choices
        • 17.1.1.4.3 Weaknesses & competitive threats
    • 17.1.2 NOOM, INC.
      • 17.1.2.1 Business overview
      • 17.1.2.2 Products & services offered
      • 17.1.2.3 Recent developments
        • 17.1.2.3.1 Product launches & enhancements
        • 17.1.2.3.2 Deals
      • 17.1.2.4 MnM view
        • 17.1.2.4.1 Right to win
        • 17.1.2.4.2 Strategic choices
        • 17.1.2.4.3 Weaknesses & competitive threats
    • 17.1.3 HINGE HEALTH, INC.
      • 17.1.3.1 Business overview
      • 17.1.3.2 Products & services offered
      • 17.1.3.3 Recent developments
        • 17.1.3.3.1 Product launches & enhancements
        • 17.1.3.3.2 Deals
      • 17.1.3.4 MnM view
        • 17.1.3.4.1 Right to win
        • 17.1.3.4.2 Strategic choices
        • 17.1.3.4.3 Weaknesses & competitive threats
    • 17.1.4 OMADA HEALTH INC.
      • 17.1.4.1 Business overview
      • 17.1.4.2 Products & services offered
      • 17.1.4.3 Recent Developments
        • 17.1.4.3.1 Product Launches & Enhancements
        • 17.1.4.3.2 Deals
      • 17.1.4.4 MnM view
        • 17.1.4.4.1 Right to win
        • 17.1.4.4.2 Strategic choices
        • 17.1.4.4.3 Weaknesses & competitive threats
    • 17.1.5 DARIOHEALTH CORP.
      • 17.1.5.1 Business overview
      • 17.1.5.2 Products & services offered
      • 17.1.5.3 Recent developments
        • 17.1.5.3.1 Product launches & enhancements
        • 17.1.5.3.2 Deals
      • 17.1.5.4 MnM view
        • 17.1.5.4.1 Right to win
        • 17.1.5.4.2 Strategic choices
        • 17.1.5.4.3 Weaknesses & competitive threats
    • 17.1.6 SWORD HEALTH, INC.
      • 17.1.6.1 Business overview
      • 17.1.6.2 Products & services offered
      • 17.1.6.3 Recent developments
        • 17.1.6.3.1 Product launches & enhancements
        • 17.1.6.3.2 Deals
    • 17.1.7 RESMED
      • 17.1.7.1 Business overview
      • 17.1.7.2 Products & services offered
      • 17.1.7.3 Recent developments
        • 17.1.7.3.1 Deals
    • 17.1.8 VIRTA HEALTH CORP.
      • 17.1.8.1 Business overview
      • 17.1.8.2 Products & services offered
      • 17.1.8.3 Recent developments
        • 17.1.8.3.1 Product launches & enhancements
        • 17.1.8.3.2 Deals
    • 17.1.9 WELLDOC, INC.
      • 17.1.9.1 Business overview
      • 17.1.9.2 Products & services offered
      • 17.1.9.3 Recent developments
        • 17.1.9.3.1 Product launches & enhancements
        • 17.1.9.3.2 Deals
    • 17.1.10 CLICK THERAPEUTICS, INC.
      • 17.1.10.1 Business overview
      • 17.1.10.2 Products & services offered
      • 17.1.10.3 Recent developments
        • 17.1.10.3.1 Product launches & enhancements
        • 17.1.10.3.2 Deals
        • 17.1.10.3.3 Other developments
    • 17.1.11 SIDEKICK HEALTH
      • 17.1.11.1 Business overview
      • 17.1.11.2 Products & services offered
      • 17.1.11.3 Recent developments
        • 17.1.11.3.1 Product launches & enhancements
        • 17.1.11.3.2 Deals
    • 17.1.12 AKILI, INC.
      • 17.1.12.1 Business overview
      • 17.1.12.2 Products & services offered
    • 17.1.13 APPLIEDVR, INC.
      • 17.1.13.1 Business overview
      • 17.1.13.2 Products & services offered
      • 17.1.13.3 Recent developments
        • 17.1.13.3.1 Deals
    • 17.1.14 WELLTHY THERAPEUTICS PVT. LTD.
      • 17.1.14.1 Business overview
      • 17.1.14.2 Products & services offered
    • 17.1.15 HEADSPACE INC.
      • 17.1.15.1 Business overview
      • 17.1.15.2 Products & services offered
        • 17.1.15.2.1 Product launches & enhancements
    • 17.1.16 LARK TECHNOLOGIES, INC.
      • 17.1.16.1 Business overview
      • 17.1.16.2 Products & services offered
    • 17.1.17 XRHEALTH
      • 17.1.17.1 Business overview
      • 17.1.17.2 Products & services offered
      • 17.1.17.3 Recent developments
        • 17.1.17.3.1 Product launches
        • 17.1.17.3.2 Deals
    • 17.1.18 AMALGAM RX, INC.
      • 17.1.18.1 Business overview
      • 17.1.18.2 Products & services offered
      • 17.1.18.3 Recent developments
        • 17.1.18.3.1 Deals
    • 17.1.19 APTAR DIGITAL HEALTH
      • 17.1.19.1 Business overview
      • 17.1.19.2 Products & services offered
      • 17.1.19.3 Recent developments
        • 17.1.19.3.1 Deals
    • 17.1.20 CANARY HEALTH
      • 17.1.20.1 Business overview
      • 17.1.20.2 Products & services offered
      • 17.1.20.3 Recent developments
        • 17.1.20.3.1 Deals
  • 17.2 START-UP/SME PLAYERS
    • 17.2.1 FREESPIRA
    • 17.2.2 MINDABLE HEALTH GMBH
    • 17.2.3 GET.ON INSTITUT FUR ONLINE GESUNDHEITSTRAININGS GMBH
    • 17.2.4 COGNIFIT INC.
    • 17.2.5 2MORROW INC.

18 RESEARCH METHODOLOGY

  • 18.1 RESEARCH APPROACH
    • 18.1.1 SECONDARY RESEARCH
      • 18.1.1.1 Key data from secondary sources
    • 18.1.2 PRIMARY RESEARCH
      • 18.1.2.1 Primary sources
      • 18.1.2.2 Key data from primary sources
      • 18.1.2.3 Breakdown of primaries
      • 18.1.2.4 Insights from primary experts
  • 18.2 RESEARCH METHODOLOGY DESIGN
  • 18.3 MARKET SIZE ESTIMATION
  • 18.4 DATA TRIANGULATION
  • 18.5 MARKET SHARE ESTIMATION
  • 18.6 STUDY ASSUMPTIONS
  • 18.7 RESEARCH LIMITATIONS
    • 18.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 18.8 RISK ASSESSMENT

19 APPENDIX

  • 19.1 DISCUSSION GUIDE
  • 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 19.3 CUSTOMIZATION OPTIONS
  • 19.4 RELATED REPORTS
  • 19.5 AUTHOR DETAILS
Show more
Product Code: HIT 4407

List of Tables

  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 DIGITAL THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 DIGITAL THERAPEUTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 4 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY OFFERING (2025)
  • TABLE 5 INDICATIVE PRICING FOR DIGITAL THERAPEUTICS SOLUTIONS, BY REGION (2025)
  • TABLE 6 DIGITAL THERAPEUTICS MARKET: KEY CONFERENCES & EVENTS 2026-2027
  • TABLE 7 CASE 1: DIGITAL THERAPEUTICS FOR IMPROVING BALANCE AND REDUCING FALL RISK
  • TABLE 8 CASE 2: DIGITAL THERAPEUTICS FOR WEIGHT MANAGEMENT AND BEHAVIOR CHANGE
  • TABLE 9 CASE 3: PRESCRIPTION DIGITAL THERAPEUTICS FOR SCHIZOPHRENIA MANAGEMENT
  • TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 11 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DIGITAL THERAPEUTICS MARKET
  • TABLE 12 DIGITAL THERAPEUTICS MARKET: LIST OF PATENTS/PATENT APPLICATIONS
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REGULATORY SCENARIO OF NORTH AMERICA
  • TABLE 19 REGULATORY SCENARIO OF EUROPE
  • TABLE 20 REGULATORY SCENARIO OF ASIA PACIFIC
  • TABLE 21 REGULATORY SCENARIO OF LATIN AMERICA
  • TABLE 22 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%)
  • TABLE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 25 UNMET NEEDS IN DIGITAL THERAPEUTICS MARKET
  • TABLE 26 END-USER EXPECTATIONS IN THE DIGITAL THERAPEUTICS MARKET
  • TABLE 27 DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 28 DIGITAL THERAPEUTICS MARKET FOR SOFTWARE/PLATFORMS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 29 DIGITAL THERAPEUTICS MARKET FOR THERAPEUTIC PROGRAMS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 30 DIGITAL THERAPEUTICS MARKET FOR IMMERSIVE & INTERFACE-BASED THERAPEUTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 32 PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 NON-PRESCRIPTION DIGITAL THERAPEUTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 34 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 35 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 36 DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 42 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 44 DIGITAL THERAPEUTICS MARKET FOR SLEEP DISORDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT & CARE-RELATED APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 49 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 DIGITAL THERAPEUTICS MARKET FOR OBESITY & WEIGHT MANAGEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 DIGITAL THERAPEUTICS MARKET FOR NUTRITION & LIFESTYLE MANAGEMENT, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 54 DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 55 DIGITAL THERAPEUTICS MARKET FOR SUBSCRIPTION-BASED MODELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 DIGITAL THERAPEUTICS MARKET FOR LICENSING (ENTERPRISE/SAAS) MODELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 DIGITAL THERAPEUTICS MARKET FOR OUTCOME-/VALUE-BASED MODELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 59 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNELS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 62 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 63 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 64 DIGITAL THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 65 DIGITAL THERAPEUTICS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 66 DIGITAL THERAPEUTICS MARKET FOR DIAGNOSTIC & REHABILITATION CENTERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 DIGITAL THERAPEUTICS MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 68 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 69 DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 70 DIGITAL THERAPEUTICS MARKET FOR PUBLIC PAYERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 DIGITAL THERAPEUTICS MARKET FOR PRIVATE PAYERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 DIGITAL THERAPEUTICS FOR EMPLOYERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 DIGITAL THERAPEUTICS FOR PATIENTS/INDIVIDUALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 DIGITAL THERAPEUTICS FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 DIGITAL THERAPEUTICS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 76 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 78 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 79 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 80 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 81 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 82 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 83 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 84 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 85 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 87 US: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 88 US: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 89 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 90 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 91 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 92 US: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 93 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 94 US: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 95 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 US: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 97 CANADA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 98 CANADA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 100 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 102 CANADA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 103 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 104 CANADA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 105 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 106 CANADA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 107 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 109 EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 111 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 113 EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 114 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 115 EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 116 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 118 GERMANY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 119 GERMANY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 121 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 GERMANY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 124 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 125 GERMANY: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 126 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 GERMANY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 FRANCE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 129 FRANCE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 130 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 131 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 FRANCE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 134 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 135 FRANCE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 136 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 137 FRANCE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 138 UK: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 139 UK: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 141 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 142 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 UK: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 144 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 145 UK: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 146 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 147 UK: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 148 ITALY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 149 ITALY: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 150 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 151 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 152 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 ITALY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 154 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 155 ITALY: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 156 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 157 ITALY: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 SPAIN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 159 SPAIN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 161 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 163 SPAIN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 164 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 165 SPAIN: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 166 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 167 SPAIN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 168 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 169 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 171 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 174 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 175 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 176 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 178 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 187 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 188 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 189 CHINA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 190 CHINA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 191 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 192 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 193 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 CHINA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 195 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 196 CHINA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 197 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 198 CHINA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 199 JAPAN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 200 JAPAN: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 202 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 203 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 204 JAPAN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 205 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 206 JAPAN: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 207 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 208 JAPAN: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 209 INDIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 210 INDIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 212 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 213 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 214 INDIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 215 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 216 INDIA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 217 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 218 INDIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 219 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 220 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 222 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 224 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 225 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 226 AUSTRALIA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 227 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 228 AUSTRALIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 229 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 230 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 232 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 233 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 234 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 235 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 236 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 237 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 238 SOUTH KOREA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 244 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 245 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 246 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 247 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 249 LATIN AMERICA: DIGITAL THERAPEUTUCS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 250 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 251 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 253 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 255 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 256 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 257 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 258 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 261 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 263 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 266 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 267 BRAZIL: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 268 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 BRAZIL: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 MEXICO: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 271 MEXICO: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 272 MEXICO: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 273 MEXICO: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 274 MEXICO: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 275 MEXICO: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 276 MEXICO: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 277 MEXICO: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 278 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 279 MEXICO: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 280 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 281 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 283 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 285 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 286 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 287 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 288 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 290 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 291 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 292 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 294 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 295 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 296 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 297 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 298 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 299 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 300 MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 301 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 302 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 303 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 305 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 307 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 308 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 309 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 310 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 312 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 313 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 314 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 315 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 318 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 319 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 320 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 SAUDI ARABIA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 322 UAE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 323 UAE: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 324 UAE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 325 UAE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 UAE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 327 UAE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 328 UAE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 329 UAE: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 330 UAE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 331 UAE: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 332 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 333 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 334 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 335 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 336 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 337 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 338 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 339 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 340 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 341 REST OF GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 342 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 343 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 345 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 346 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 347 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 348 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 349 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 350 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 351 SOUTH AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2024-2031 (USD MILLION)
  • TABLE 354 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 355 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT & CARE-RELATED APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 356 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 357 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2024-2031 (USD MILLION)
  • TABLE 358 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2024-2031 (USD MILLION)
  • TABLE 359 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 360 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 361 REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 362 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, JANUARY 2023-JULY 2026
  • TABLE 363 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION
  • TABLE 364 DIGITAL THERAPEUTICS MARKET: REGION FOOTPRINT
  • TABLE 365 DIGITAL THERAPEUTICS MARKET: OFFERING FOOTPRINT
  • TABLE 366 DIGITAL THERAPEUTICS MARKET: APPLICATION FOOTPRINT
  • TABLE 367 DIGITAL THERAPEUTICS MARKET: REVENUE MODEL FOOTPRINT
  • TABLE 368 DIGITAL THERAPEUTICS MARKET: END-USER FOOTPRINT
  • TABLE 369 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 370 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION
  • TABLE 371 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY COMPONENT
  • TABLE 372 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 373 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2023-JULY 2026
  • TABLE 374 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2023-JULY 2026
  • TABLE 375 TELADOC HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 376 TELADOC HEALTH, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 377 TELADOC HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 378 TELADOC HEALTH, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 379 NOOM, INC.: COMPANY OVERVIEW
  • TABLE 380 NOOM, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 381 NOOM, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 382 NOOM, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 383 HINGE HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 384 HINGE HEALTH, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 385 HINGE HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 386 HINGE HEALTH, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 387 OMADA HEALTH INC.: COMPANY OVERVIEW
  • TABLE 388 OMADA HEALTH INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 389 OMADA HEALTH INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 390 OMADA HEALTH INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 391 DARIOHEALTH CORP.: COMPANY OVERVIEW
  • TABLE 392 DARIOHEALTH CORP.: PRODUCTS & SERVICES OFFERED
  • TABLE 393 DARIOHEALTH CORP.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 394 DARIOHEALTH CORP.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 395 SWORD HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 396 SWORD HEALTH, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 397 SWORD HEALTH, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JUNE 2026
  • TABLE 398 SWORD HEALTH, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 399 RESMED: COMPANY OVERVIEW
  • TABLE 400 RESMED: PRODUCTS & SERVICES OFFERED
  • TABLE 401 RESMED: DEALS, JANUARY 2023-JULY 2026
  • TABLE 402 VIRTA HEALTH CORP.: COMPANY OVERVIEW
  • TABLE 403 VIRTA HEALTH CORP.: PRODUCTS & SERVICES OFFERED
  • TABLE 404 VIRTA HEALTH CORP.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 405 VIRTA HEALTH CORP.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 406 WELLDOC, INC.: COMPANY OVERVIEW
  • TABLE 407 WELLDOC, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 408 WELLDOC, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 409 WELLDOC, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 410 CLICK THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 411 CLICK THERAPEUTICS, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 412 CLICK THERAPEUTICS, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 413 CLICK THERAPEUTICS, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 414 CLICK THERAPEUTICS, INC.: OTHER DEVELOPMENTS, JANUARY 2023-JUNE 2026
  • TABLE 415 SIDEKICK HEALTH: COMPANY OVERVIEW
  • TABLE 416 SIDEKICK HEALTH: PRODUCTS & SERVICES OFFERED
  • TABLE 417 SIDEKICK HEALTH: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 418 SIDEKICK HEALTH: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 419 AKILI, INC.: COMPANY OVERVIEW
  • TABLE 420 AKILI, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 421 APPLIEDVR, INC.: COMPANY OVERVIEW
  • TABLE 422 APPLIEDVR, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 423 APPLIEDVR, INC.: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 424 WELLTHY THERAPEUTICS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 425 WELLTHY THERAPEUTICS PVT LTD: PRODUCTS & SERVICES OFFERED
  • TABLE 426 HEADSPACE INC.: COMPANY OVERVIEW
  • TABLE 427 HEADSPACE INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 428 HEADSPACE INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023-JULY 2026
  • TABLE 429 LARK TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 430 LARK TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 431 XRHEALTH: COMPANY OVERVIEW
  • TABLE 432 XRHEALTH: PRODUCTS & SERVICES OFFERED
  • TABLE 433 XRHEALTH: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
  • TABLE 434 XRHEALTH: DEALS, JANUARY 2023-JULY 2026
  • TABLE 435 AMALGAM RX, INC.: COMPANY OVERVIEW
  • TABLE 436 AMALGAM RX, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 437 AMALGAM RX, INC.: DEALS, JANUARY 2023-JULY 2026
  • TABLE 438 APTAR DIGITAL HEALTH: COMPANY OVERVIEW
  • TABLE 439 APTAR DIGITAL HEALTH: PRODUCTS & SERVICES OFFERED
  • TABLE 440 APTAR DIGITAL HEALTH: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 441 CANARY HEALTH: COMPANY OVERVIEW
  • TABLE 442 CANARY HEALTH: PRODUCTS & SERVICES OFFERED
  • TABLE 443 CANARY HEALTH: DEALS, JANUARY 2023-JUNE 2026
  • TABLE 444 RISK ASSESSMENT: DIGITAL THERAPEUTICS MARKET

List of Figures

  • FIGURE 1 DIGITAL THERAPEUTICS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 MARKET SCENARIO
  • FIGURE 3 GLOBAL DIGITAL THERAPEUTICS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2023-2026
  • FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL THERAPEUTICS MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS IN DIGITAL THERAPEUTICS MARKET, 2026-2031
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL THERAPEUTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 8 RISING DEMAND FOR DIGITAL HEALTHCARE AND PATIENT-CENTRIC CARE TO DRIVE GROWTH IN DIGITAL THERAPEUTICS MARKET
  • FIGURE 9 PRESCRIPTION DIGITAL THERAPEUTICS IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2025
  • FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 11 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 12 DIGITAL THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 13 DIGITAL THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 14 DIGITAL THERAPEUTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 17 PATENT PUBLICATION TRENDS IN DIGITAL THERAPEUTICS MARKET, 2015-2026
  • FIGURE 18 JURISDICTION & TOP APPLICANT ANALYSIS FOR DIGITAL THERAPEUTICS MARKET
  • FIGURE 19 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DIGITAL THERAPEUTICS MARKET (JANUARY 2015-JULY 2026)
  • FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON DIGITAL THERAPEUTICS ACROSS INDUSTRIES
  • FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS
  • FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
  • FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • FIGURE 24 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT
  • FIGURE 25 ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET SNAPSHOT
  • FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2021-2025
  • FIGURE 27 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET (2025)
  • FIGURE 28 DIGITAL THERAPEUTICS MARKET: BRAND COMPARATIVE ANALYSIS
  • FIGURE 29 EV/EBITDA OF KEY VENDORS
  • FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 31 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 33 DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 34 TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 35 HINGE HEALTH, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 36 OMADA HEALTH INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 DARIOHEALTH CORP.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 RESMED: COMPANY SNAPSHOT (2025)
  • FIGURE 39 APTAR DIGITAL HEALTH: COMPANY SNAPSHOT (2025)
  • FIGURE 40 RESEARCH DESIGN
  • FIGURE 41 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 42 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 43 BOTTOM-UP APPROACH
  • FIGURE 44 TOP-DOWN APPROACH
  • FIGURE 45 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF DIGITAL THERAPEUTICS INDUSTRY
  • FIGURE 46 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 47 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!